Metastatic breast cancer indication to be pursued for (Z)-endoxifen
Dr. Steven Quay, Chairman and Chief Executive Officer of Atossa Therapeutics, stated: “Our decision to advance (Z)-endoxifen into a metastatic breast cancer indication underscores our unwavering commitment to developing a best-in-class therapy for women facing this devastating disease. The encouraging clinical data that has been generated to date supports the potential of (Z)-endoxifen to provide a meaningful benefit to patients who have exhausted other treatment options. By pursuing this strategy, we believe we are not only addressing an urgent medical need but also fortifying the path forward for expanding (Z)-endoxifen’s role across the full spectrum of breast cancer prevention and treatment. We look forward to providing future updates as we execute this plan.”
Share:
More News
“Initiation of the TEADCO Phase 1b/2 basket trial is another important milestone for the ODM-212 clinical development program and reflects our commitment to patients with difficult-to-treat cancers,” said Professor Outi Vaarala, Executive Vice President, Research & Development at Orion. “Together with the ongoing TEADES study, TEADCO highlights the versatility of
“In this study, tovecimig showed an impressive overall response rate which translated into a clinically meaningful and highly statistically significant improvement in PFS for patients with previously treated BTC. The remarkable 56% reduction in the risk of disease progression is unprecedented in this patient population without an actionable mutation in
“We are encouraged to see taletrectinib (IBTROZI) added to the NCCN Guidelines® for CNS Cancers given its demonstrated high rates of intracranial response that are durable in ROS1+ NSCLC patients with brain metastases,” said David Hung, M.D., Founder, President and Chief Executive Officer of Nuvation Bio. “Given the prevalence of
Daniel Getts, Ph.D., CEO of CREATE, added “MT-304 is proof of what our platform can do, and what our team can execute. Our mRNA-LNP leadership enables us to move from concept to clinic with remarkable speed. Just last weekend at AACR, we presented compelling preclinical data across our in vivo